Warner Bros. Discovery (WBD) to be acquired by Netflix (NFLX) for $72 billion

Netflix (NFLX) has entered into a definitive agreement to acquire Warner Bros. Discovery (WBD) in a cash and stock transaction worth $72 billion was perhaps the most widely discussed happening today. 

• Paramount Skydance (PSKY), which also submitted a bid for WBD traded sharply lower, with CNBC reporting that the company is considering taking a direct bid to WBD's shareholders. 
• If approved, this marks Netflix’s transformation from streaming disruptor to Hollywood establishment power. But the move could trigger the defining antitrust battle of the streaming era, testing whether regulators will allow one company to dominate both content creation and distribution at this scale.

The details:

Netflix would acquire Warner Bros.’ film and TV studios plus HBO and Max, in a transaction valuing the business at about $82.7B. The combined entity would merge Netflix’s 300M+ subscribers with WB’s century-old legacy and franchises like Harry Potter, DC titles, and HBO series. The deal faces intense regulatory scrutiny, with the Directors Guild of America and exhibition groups already warning of dire consequences for filmmaking. Netflix is offering a $5B breakup fee if regulators block the deal, signaling its commitment despite antitrust concerns.

Paramount Skydance Corporation (PSKY)

David Ellison (son of Oracle co-founder Larry Ellison) founded Skydance Media in 2010 with a vision to create premium, franchise-driven content. His leadership and financial backing transformed it into a major independent studio, culminating in the 2025 merger with Paramount Global to form Paramount Skydance Corporation (PSKY).

Ero Copper (ERO) +17%

Ero Copper Corp. engages in the exploration, development, and production of mining projects in Brazil. 

Its flagship asset includes Caraíba operations that comprise the production and sale of copper concentrates located in northeastern Bahia State, Brazil, as well as gold and silver produced and sold as by-products. 

• Sector: Basic Materials
• Industry: Copper
• Full Time Employees: 3,690
• Incorporated in 2016 
• Headquartered in Vancouver, Canada
• https://erocopper.com

==Alarum Technologies Ltd. (ALAR) reported earnings on Wed 26 Nov 25 (b/o)

 

Alarum Technologies Ltd. (NASDAQ: ALAR) was formerly known as Safe-T Group Ltd. and rebranded to Alarum (ALAR) in Jan 2023

Sector: Technology

Industry: Software - Infrastructure

Full Time Employees: 68

Founded in 2013 

Headquartered in Tel Aviv, Israel

https://www.alarum.io

Alarum Technologies today reported record Q3 2025 results—revenue $13.0M (+81% y/y), net profit $0.1M and $1.2M adjusted EBITDA—and guided Q4 to about $12M revenue and ~$1M adjusted EBITDA, citing strong AI training-data demand.

===Novo Nordisk (NVO) : Ozempic pill failed to slow Alzheimer’s progression in two large studies.

 

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

• Co announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer's disease indication with semaglutide was based on real-world evidence studies, pre-clinical models as well as post-hoc analyses from diabetes and obesity tria
• The evoke and evoke+ trials did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimer's disease, as measured by the change in Clinical Dementia Rating -- Sum of Boxes score compared to baseline. While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in both trials, this did not translate into a delay of disease progression.
• In the evoke trials with patients aged 55-85, suffering from mild cognitive impairment or mild dementia due to Alzheimer's disease, semaglutide appeared to have a safe and well-tolerated profile consistent with previous semaglutide trials. To date, more than 37 million patient-years of semaglutide exposure have occurred across